Director Raymond George Hill of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share.

Key Highlights

  • Reporting Person: Raymond George Hill, identified as a Director of Addex Therapeutics Ltd. (NASDAQ:ADXN)
  • Transaction Date: November 11, 2026, with transaction code "A" (acquisition)
  • Options Acquired: 942,854 stock options (rights to buy common stock) at an exercise price of $0.026 per share
  • Vesting Schedule: Options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026
  • Expiration Date: November 10, 2036
  • Price of Derivative Security: $0 (as reported in the filing)
  • Total Derivative Securities Held Following Transaction: 1,215,961 stock options, held directly

Hill Acquires 942,854 Addex Therapeutics Stock Options in November 2026 Grant

According to the Form 4 filing submitted on November 13, 2026, Addex Therapeutics Ltd. director Raymond George Hill acquired 942,854 stock options on November 11, 2026. The filing identifies these as stock options carrying a right to buy shares, with each option granting the right to purchase one ADXN share listed on SIX Swiss Exchange, as explained in the filing's response notes.

The exercise price is reported as $0.026 per share in U.S. dollars. The filing notes that this figure "reflects the conversion from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026." The price of the derivative security at acquisition is reported as $0. Following this transaction, Hill beneficially owns 1,215,961 derivative securities in total on a direct basis, according to the filing.

The filing states that the options vest "in equal monthly installments over a 4-year period beginning at the exercisable date," which is listed as November 11, 2026. The options expire on November 10, 2036. Hill's address is listed as Geneva, Switzerland. The form was signed by Lenaic Nathanael Teyssedou by power of attorney on November 13, 2026.

What Was Disclosed

Addex Therapeutics director Raymond George Hill reported the acquisition of 942,854 stock options on November 11, 2026, at an exercise price of $0.026 per share, with a 4-year monthly vesting schedule and an expiration date of November 10, 2036.